Related references
Note: Only part of the references are listed.Decision support methods for the detection of adverse events in post-marketing data
M. Hauben et al.
DRUG DISCOVERY TODAY (2009)
Informatic tools and approaches in postmarketing pharmacovigilance used by FDA
Joyce Weaver et al.
AAPS JOURNAL (2008)
Obstacles and opportunities in new drug development
K. I. Kaitin
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacovigilance:: methods, recent developments and future perspectives
L. Harmark et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Tectonic shifts in the health information economy
Kenneth D. Mandl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction
John S. Brownstein et al.
PLOS ONE (2007)
Outlook - Can open-source R&D reinvigorate drug research?
Bernard Munos
NATURE REVIEWS DRUG DISCOVERY (2006)
Estimating the cost of new drug development: Is it really $802 million?
CP Adams et al.
HEALTH AFFAIRS (2006)
Pharmaceuticals - A new grammar for drug discovery
MC Fishman et al.
NATURE (2005)
Drug repositioning: Identifying and developing new uses for existing drugs
TT Ashburn et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Are the economics of pharmaceutical research and development changing? Productivity, patents and political pressures
H Grabowski
PHARMACOECONOMICS (2004)
The price of innovation: new estimates of drug development costs
JA DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2003)
Share Paper
